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ABSTRACT
Amifostine (S-2[3-aminopropylamino]ethyl phosphorothioate) and one of its analogues,
DRDE-07 (S-2[2-aminoethylamino]ethyl phenyl sulphide) are promising prophylactic agents for
sulphur mustard (SM; a blistering agent) toxicity. When given orally, DRDE-07 was more effective
than amifostine as a prophylactic agent against SM administered percutaneously. Various
pharmacological and toxicological studies are required before the introduction of a chemical as
a drug. The respiratory effects of amifostine and DRDE-07 were carried out in rats using a body
plethysmograph fitted with a volumetric pressure transducer for sensing the respiratory flow
signals. The signals were amplified, digitised, and stored on a personal computer for further
analysis. After taking control recordings of respiratory signals, different doses (0.5 LD50, 1.0 LD50
and 2.0 LD50) of amifostine and DRDE-07 were administered orally (LD50 amifostine = 2262 mg/
kg; DRDE-07 = 1599 mg/kg), and the respiratory changes were monitored for 4 h. Amifostine and
DRDE-07 showed a uniform breathing pattern even in 2.0 LD50 dose. However, a significant dose-
dependent decrease in respiratory frequency was observed following amifostine administration.
DRDE-07 did not show any significant change. The tidal volume was not altered significantly
both in amifostine and DRDE-07 administered animals. The study shows that DRDE-07, even in
lethal doses, may not affect the respiration immediately, whereas, amifostine may decrease the
respiratory frequency.
 Keywords: Amifostine, DRDE-07, toxicity, respiratory frequency, tidal volume, prophylactic agents,
sulphur mustard antidote, cytoprotective drug, sulphur mustard
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1. INTRODUCTION
The nerve agents and blistering agents continue
to be a threat as chemical warfare agents against
the armed forces in spite of the control imposed
by the Chemical Weapon Convention (CWC). The
CWC prohibits the production, storage, transport,
and use of chemicals on enemy forces1. One such
chemical is sulphur mustard (SM), commonly known
as mustard gas. It is included in the Schedule I of
the CWC. Reports are available of its use in several
instances before the CWC came into force2-4. State
Parties, that have declared possessing SM, are in
the process of destroying it. In spite of the CWC,
the threat exists that SM can be used clandestinely
during war or by terrorist organisations because of
its simple method of preparation.
The chemical name of SM is “2,2'-dichloro
diethyl sulphide”, and it is an alkylating agent. SM
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causes serious blisters upon contact with human
skin. In animal models, it is extremely lethal. Just
one microlitre applied on the skin of a mouse or
a rat may be lethal in a weeks time. SM forms
sulphonium ion in the body and alkylates DNA,
leading to DNA strand breaks and cell death5-6.
Due to high electrophilic property of the sulphonium
ion, SM binds to a variety of cellular macromolecules
and death occurs due to multi-organ failure7-8. Eyes,
skin, and respiratory tract are the principal target
organs of SM toxicity5,9-10.
Several antidotes have been reported for the
systemic toxicity of SM in experimental animals,
but none of these have been recommended so
far8,11-14. SM is highly lipophilic and is absorbed
quickly on contact with the skin. The effective
method of reducing the toxicity of SM is by
decontamination immediately after the contact7.
The most commonly used decontaminant is Fuller's
earth (a native form of aluminium silicate) that
removes SM by adsorption, thereby reducing the
toxicity 15. Few chemical decontaminants for human
use have also shown very good efficacy16-17.
An effective prophylactic agent against SM is
the need of the day, especially for personnel engaged
in the destruction of SM and during inspection by
the Organisation for Prohibition of Chemical Weapons
(OPCW). From a series of aminothiols, two compounds,
amifostine (S-2[3-aminopropylamino] ethyl phosphoro-
thioate) and DRDE-07 (S-2[2-aminoethylamino]ethyl
phenyl sulphide) gave very good protection as a
prophylactic agent against SM18-20. When given
orally, DRDE-07 was more effective than amifostine
as a prophylactic agent against SM administered
percutaneously19,21. Various pharmacological and
toxicological studies are needed, before the introduction
of a chemical as a drug. Several of these studies
have been initiated and the effect of amifostine
and DRDE-07 on respiratory variables in rats has
been reported here.
2 . MATERIALS
Randomly bred Wistar male rats (175-225 g,
body weight) from DRDE Animal Facility were
used. They were housed in polypropylene cages,
4 rats per cage) with dust-free rice husk as bedding
material, and were provided with food (supplied by
Amruth India Ltd) and water ad libitum. The care
and upkeep of the animals were as per the approved
guidelines of the Committee for the Purpose of
Control and Supervision of Experiments on Animals,
India. This study has the approval of the DRDE’s
Animal Ethical Committee.
Amifostine, (S-2[3-aminopropylamino]ethyl
phosphorothioate) and DRDE-07, (S-2[2-aminoethyl-
amino]ethyl phenyl sulphide) were synthesised in
the chemistry laboratory. The compounds were
characterised by elemental analysis, IR, 1H NMR,
and mass spectral analysis. The purity was assessed
by thin layer chromatography. Amifostine and DRDE-07
were used as their hydrochlorides and these were
water soluble. All other chemicals used were of
analytical grade.
Amifostine : NH 2–CH2–CH2–CH2–NH–CH2–CH2–
S–PO 3–H 2
DRDE-07 : NH2–CH 2–CH 2–NH–CH2–CH 2–S–
C 6H 5
3 . METHODOLOGY
Four rats at a time were restrained in body
plethysmographs for the recording of respiratory
signals (Fig. 1). The glass plethysmographs (length
140 mm and dia 45 mm) can accommodate rats
weighing between 150 g to 250 g. A volumetric
pressure transducer (model PT5, Grass Instrument,
USA) was used for sensing respiratory flow signals.
A continuous air flow of 170 ml.min-1 was maintained
into each body plethysmograph using a critical orifice
(27 gauge needle). The signals from the individual
transducers were amplified using universal amplifiers
(Gould, USA). The amplified signals were digitised
using an analog-to-digital converter (Metrabyte,
Taunton, USA) and stored on a personal computer
and analysed. The amplified signals were also fed
into an oscillograph for recording of breathing pattern
(WindoGraf, Gould, USA). A computer programme
developed by the University of Pittsburgh, USA for
monitoring of respiratory changes in small animals
was used for recording of various respiratory variables22.
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The animals were acclimatised in the body
plethysmographs for 30 min. After the
acclimatisation, a control recording of respiratory
variables was carried out for 30 min. Amifostine
and DRDE-07 were given using an oral feeding
cannula (20 gauge, Harvard Instruments, USA)
and the respiratory variables were recorded
for a period of 4 h after administration of the
dose. Three doses of amifostine and DRDE-
07 (0.5 LD50, 1.0 LD50 and 2.0 LD50) were
given (oral LD 50 amifostine = 2262 mg/kg; DRDE-
07 = 1599 mg/kg). For each dose, four rats
were used. Four rats served as control, and
were administered saline only.
All the values obtained were converted as
per cent of pre-drug administration values and
expressed as mean ± standard error. The means
were analysed by one way ANOVA, followed
by Dunnett's test. SigmaStat (Jandel Scientific,
San Rafael, USA) was used for all the statistical
analysis. A probability of less than 0.05 was
taken as statistically significant.
4 . RESULTS
No rat died during the monitoring period of 4 h
following 0.5 LD50 and 1.0 LD50 of amifostine and
DRDE-07. Two rats died during the monitoring
period following 2.0 LD50 of DRDE-07, but none
in the amifostine group. But all the rats administered
with 2.0 LD50 of amifostine and DRDE-07 died
within 24 h. Three rats of amifostine and two rats
of DRDE-07 in 1.0 LD50 group died within 24 h.
All the rats given 0.5 LD50 of aminofostine and
DRDE-07 survived.
The normal value for tidal volume was 0.260
± 0.021 ml.min–1 and respiratory frequency was
134 ± 5 min–1 (mean ± SEM; n = 28). Control
animals (saline group) showed a uniform breathing
pattern during the 4 h monitoring period (Fig. 2).
A dose of 0.5 LD50 of amifostine and DRDE-07
also showed a uniform breathing pattern. A dose
of 1.0 LD50 and 2.0 LD50 of amifostine showed
a disturbed breathing pattern. There was not much
change in the DRDE-07 groups. The breathing
patterns of 1.0 LD50 amifostine and DRDE-07 are
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Figure 1. Schematic diagram of the respiratory analysis setup
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shown in Figs 3 and 4. Tables 1 and 2 show the
respiratory frequency and tidal volume of various
doses of amifostine and DRDE-07 calculated from
the online computer program. There was a significant
dose-dependent and time-dependent decrease in
the respiratory frequency following oral administration
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Figure 2. Time response analysis for breath classification and measured variables for a group of four rats: (a)  before and (b)
after oral administration of saline (control). The arrow indicates the time of administration.
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of amifostine. But, DRDE-07 did not show any
significant change. The tidal volume was not altered
in amifostine and DRDE-07 administered rats.
5 . DISCUSSION
Even after several decades of active research,
a suitable antidote for the toxic effects of SM has
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Figure 3. Time response analysis for breath classification and measured variables for a group of four rats: (a) before and (b)
after oral administration of 1.0 LD50 of amifostine. The arrow indicates the time of administration.
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not been developed. The present method of reducing
the toxic effects of SM are by physical and chemical
decontamination7,16,17.
Amifostine is extensively studied as a cytoprotective
drug23. Amifostine, when given prophylactically for
chemotherapeutic agents like cisplatin and
Figure 4. Time response analysis for breath classification and measured variables for a group of four rats: (a) before and (b)
after oral administration of 1.0 LD50 of DRDE-07.  The arrow indicates the time of administration.
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cyclophosphamide, has been shown to protect selectively
normal tissues without reducing the cytotoxic effects
on the cancer cells24-27. Amifostine has also been
shown to be effective against carbon tetrachloride-
induced liver necrosis, and to protect tissues from
the toxicities of radiation and alkylating agents,
probably by scavenging the generated free radicals25,28-30.
This triggered interest of the authors in amifostine
and its analogues as a prophylactic agent against
SM toxicity. Evaluation of these analogues revealed
that DRDE-07 is a promising prophylactic agent for
SM 18. The initial studies by the authors revealed that
intraperitoneal administration of amifostine was better
than DRDE-07, but by the oral route, DRDE-07 showed
very good protection against SM than amifostine19,20.
The cytoprotective effect of amifostine is due
to its free thiol metabolite that is formed by the
action of the membrane-bound alkaline phosphatase23,29.
Since DRDE-07 does not have a phosphate group,
its further metabolism and mechanism of protection
is not understood so far. It is expected that due
to the presence of an aryl group in DRDE-07, the
lipophilicity of the compound is increased with a
Effect after 
Agent Dose 
1 h 2 h 3 h 4 h 
Control Saline 105.9  8.0 107.6  5.3 109.0  8.1 108.9  9.8 
Amifostine 0.5 LD50 93.1  1.9 86.0  1.4 84.8  3.1 83.1  6.0* 
Amifostine 1.0 LD50 82.5  2.6 74.8  2.9 68.4  1.7* 68.0  2.5* 
Amifostine 2.0 LD50 82.4  6.1 74.8  2.9 55.8  2.0* 52.9  2.7* 
DRDE-07 0.5 LD50 93.4  6.1 94.4  5.4 91.3  7.1 94.0  6.2 
DRDE-07 1.0 LD50 98.7  5.1 110.0  10.2 111.9  13.6 107.7  9.5 
DRDE-07# 2.0 LD50 117.5 127.9 113.3 106.7 
F - 2.14 3.83 9.05 10.40 
P - NS < 0.05 < 0.001 < 0.001 
 
Table 1.  Effect of oral administration of amifostine and DRDE-07 on respiratory frequency in rats
Values are in per cent; mean ± SE (n = 4; #n = 2); * Statistically significant from control of the same time period
Table 2.  Effect of oral administration of amifostine and DRDE-07 on tidal volume in rats
Values are in per cent; mean ± SE (n = 4; #n = 2); * Statistically significant from control of the same time period
Effect after 
Agent Dose 
1 h 2 h 3 h 4 h 
Control Saline 90.8  7.7 99.1  9.6 101.3  23.2 117.5  28.0
Amifostine 0.5 LD50 91.0  9.4 96.8  15.6 105.0  18.5 135.2  23.3
Amifostine 1.0 LD50 112.8  12.2 121.5  12.1 128.5  14.7 127.2  17.8
Amifostine 2.0 LD50 126.4  16.7 154.1  31.6 162.2  35.3 155.8  27.2
DRDE-07 0.5 LD50 104.7  8.4 133.0  14.7 118.4  6.3 105.3  21.2
DRDE-07 1.0 LD50 109.5  9.5 111.1  18.6 102.5  19.0 97.0  20.0
DRDE-07# 2.0 LD50 111.0 102.5 159.6 131.5 
F - 0.98 1.16 0.82 0.55 
P - NS NS NS NS 
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better bioavailability. Amifostine gave a protection
of 9.5-fold compared to 27-fold protection of DRDE-
07 in mouse model against SM toxicity. But in rat
model, both amifostine and DRDE-07 gave about
2-fold to 3-fold protection21.
Various pharmacological and toxicological data
were generated on amifostine and DRDE-07. The
earlier study by the authors revealed that oral
administration of DRDE-07 induced a dose-dependent
decrease in mean arterial blood pressure and the
effects were pronounced at 1.0 LD50 and 2.0 LD50
doses31. Oral administration of amifostine also decreased
mean arterial blood pressure at 1.0 LD50 and 2.0 LD50
doses (unpublished). The computer program developed
for measuring respiratory variables of inhaled chemicals
was used conveniently for the oral administration
of amifostine and DRDE-0722.
In the present study, a significant dose-dependent
and time-dependent decrease in respiratory frequency
were observed following oral administration of
amifostine. But, no significant change was observed
following oral administration of DRDE-07. The changes
that were observed following oral administration of
amifostine were also of slow onset. A variety of
drugs that act as the central nervous system depressants,
viz., general anaesthetics, opioid analgesics, sedatives,
and hypnotics cause a depression of respiration,
and respiratory stimulants like doxapram and nikethamide
cause an increase in the respiratory frequency and
tidal volume32. DRDE-07 did change the respiratory
frequency, showing that it may not have any depressant
or stimulant action on the central nervous system. The
decrease in respiratory frequency shown by amifostine
may be due to its central or peripheral action.
The present study shows that DRDE-07, even
in lethal doses, may not affect the respiration immediately,
whereas amifostine may decrease the respiratory
frequency.
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